These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2038 related articles for article (PubMed ID: 10553163)

  • 21. [The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma].
    Biesma B; Willemse PH; Vellenga E; Limburg PC; Aalders JG; de Vries EG
    Ned Tijdschr Geneeskd; 1991 Mar; 135(10):420-4. PubMed ID: 2020314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combined effects of interleukin-11, stem cell factor, and granulocyte colony-stimulating factor on newborn rat hematopoiesis: significant enhancement of the absolute neutrophil count.
    Cairo MS; Plunkett JM; Schendel P; van de Ven C
    Exp Hematol; 1994 Oct; 22(11):1118-23. PubMed ID: 7523164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys.
    Krumwieh D; Weinmann E; Siebold B; Seiler FR
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():229-47; discussion 247-8. PubMed ID: 1691245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
    Neidhart JA
    Cancer; 1992 Aug; 70(4 Suppl):913-20. PubMed ID: 1379115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation.
    Atkinson K; Vos B; Kang-Er Z; Guiffre A; Seymour R; Gillis S
    Cytokines Mol Ther; 1995 Mar; 1(1):47-55. PubMed ID: 9384663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
    Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
    Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
    Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
    Juweid ME; Blumenthal RD; Lew W; Hajjar G; Rubin AD; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mobilization of autologous peripheral blood stem cells by chemotherapy and recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)].
    Cui X; Shao Y; Ren B; Tong Z; Ren X; Li L; Zhang Z; Zhang N; Dai R; Hao X
    Zhonghua Xue Ye Xue Za Zhi; 2000 May; 21(5):247-9. PubMed ID: 11876989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.